{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T04:43:07Z","timestamp":1773290587298,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL-102035"],"award-info":[{"award-number":["HL-102035"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2020J01996"],"award-info":[{"award-number":["2020J01996"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jtha.2024.07.023","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T12:47:06Z","timestamp":1723121226000},"page":"3035-3047","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1243-3607","authenticated-orcid":false,"given":"Yingyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn A.","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiqing","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-0708","authenticated-orcid":false,"given":"Qizhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.023_bib1","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.023_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2516.2009.02197.x","article-title":"Assessing risk factors: prevention of inhibitors in haemophilia","volume":"16","author":"Chambost","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.023_bib3","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1160\/TH16-01-0049","article-title":"The burden of inhibitors in haemophilia patients","volume":"116","author":"Walsh","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.023_bib4","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/a-1727-1384","article-title":"Emicizumab for all pediatric patients with severe hemophilia A","volume":"42","author":"Wieland","year":"2022","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2024.07.023_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211032452","article-title":"Design of an international investigator-initiated study on modern treatment of inhibitor-positive patients with haemophilia A (MOTIVATE)","volume":"12","author":"Escuriola Ettingshausen","year":"2021","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2024.07.023_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1019275","article-title":"Hemophilia a patients with inhibitors: mechanistic insights and novel therapeutic implications","volume":"13","author":"Luo","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.07.023_bib7","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa2113708","article-title":"Gene therapy for hemophilia A. Reply","volume":"386","author":"Ozelo","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.023_bib8","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.023_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.023_bib10","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.omtm.2018.01.011","article-title":"Platelet-targeted gene therapy for hemophilia","volume":"9","author":"Shi","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2024.07.023_bib11","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1111\/jth.13800","article-title":"Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated","volume":"15","author":"Chen","year":"2017","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.023_bib12","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1038\/s41409-021-01447-y","article-title":"Fludarabine\/busulfan versus busulfan\/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis","volume":"56","author":"Kurosawa","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.07.023_bib13","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2020.248187","article-title":"Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: improved outcomes over two decades","volume":"106","author":"Cooper","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.07.023_bib14","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1182\/blood-2014-02-514778","article-title":"Conditioning regimens for hematopoietic cell transplantation: one size does not fit all","volume":"124","author":"Gyurkocza","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.023_bib15","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbmt.2014.01.009","article-title":"Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia","volume":"20","author":"Gyurkocza","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.07.023_bib16","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1080\/16078454.2021.1881228","article-title":"Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis","volume":"26","author":"Edahiro","year":"2021","journal-title":"Hematology"},{"key":"10.1016\/j.jtha.2024.07.023_bib17","doi-asserted-by":"crossref","first-page":"921.e1","DOI":"10.1016\/j.jtct.2021.08.007","article-title":"Fludarabine and melphalan compared with reduced doses of busulfan and fludarabine improve transplantation outcomes in older patients with myelodysplastic syndromes","volume":"27","author":"Oran","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtha.2024.07.023_bib18","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/bloodadvances.2020003654","article-title":"Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors","volume":"5","author":"Grunwald","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.023_bib19","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1080\/10428194.2017.1361027","article-title":"Myeloablative busulfan\/cytoxan conditioning versus reduced-intensity fludarabine\/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia","volume":"59","author":"Dhere","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2024.07.023_bib20","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.3324\/haematol.2018.214429","article-title":"Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial","volume":"104","author":"Mehta","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.07.023_bib21","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","article-title":"Fludarabine\/busulfan versus fludarabine\/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma","volume":"22","author":"Kekre","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.07.023_bib22","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.bbmt.2016.04.026","article-title":"Fludarabine-busulfan reduced-intensity conditioning in comparison with fludarabine-melphalan is associated with increased relapse risk in spite of pharmacokinetic dosing","volume":"22","author":"Damlaj","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.07.023_bib23","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1080\/10428194.2020.1731498","article-title":"Reduced-intensity fludarabine\/melphalan confers similar survival to busulfan\/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia","volume":"61","author":"DiMaggio","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtha.2024.07.023_bib24","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1586\/14737140.7.7.945","article-title":"Melphalan and its role in the management of patients with multiple myeloma","volume":"7","author":"Falco","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.jtha.2024.07.023_bib25","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1111\/j.1538-7836.2012.04791.x","article-title":"Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity","volume":"10","author":"Kuether","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.023_bib26","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.jtha.2022.10.006","article-title":"Pre-existing anti-factor VIII immunity alters therapeutic platelet-targeted factor VIII engraftment following busulfan conditioning through cytotoxic CD8 T cells","volume":"21","author":"Jing","year":"2023","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.023_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/ng0595-119","article-title":"Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A","volume":"10","author":"Bi","year":"1995","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtha.2024.07.023_bib28","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1182\/bloodadvances.2019000516","article-title":"Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice","volume":"3","author":"Gao","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.023_bib29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1538-7836.2007.02346.x","article-title":"Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A","volume":"5","author":"Shi","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.023_bib30","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3389\/fimmu.2018.01950","article-title":"Platelet gene therapy promotes targeted peripheral tolerance by clonal deletion and induction of antigen-specific regulatory T cells","volume":"9","author":"Luo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.07.023_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.omtn.2020.12.026","article-title":"Platelet gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of antigen-specific T cells","volume":"23","author":"Li","year":"2021","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jtha.2024.07.023_bib32","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1182\/blood-2008-02-138214","article-title":"Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity","volume":"112","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.023_bib33","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-08-662916","article-title":"The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity","volume":"127","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.023_bib34","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/mt.2013.197","article-title":"Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice","volume":"22","author":"Chen","year":"2014","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.023_bib35","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1111\/jth.12633","article-title":"In\u00a0vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection","volume":"12","author":"Schroeder","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.023_bib36","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/jth.14379","article-title":"The impact of GPIbalpha on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity","volume":"17","author":"Chen","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.023_bib37","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1182\/bloodadvances.2020004071","article-title":"Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity","volume":"5","author":"Schroeder","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.023_bib38","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1172\/JCI28416","article-title":"Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies","volume":"116","author":"Shi","year":"2006","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jtha.2024.07.023_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.774348","article-title":"Total body irradiation in haematopoietic stem cell transplantation for paediatric acute lymphoblastic leukaemia: review of the literature and future directions","volume":"9","author":"Hoeben","year":"2021","journal-title":"Front Pediatr"},{"key":"10.1016\/j.jtha.2024.07.023_bib40","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.clml.2023.01.004","article-title":"Total body irradiation versus chemotherapy conditioning in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplant: a systematic review and meta-analysis","volume":"23","author":"Rehman","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtha.2024.07.023_bib41","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1038\/s41409-018-0356-5","article-title":"Preconditioning with fludarabine, busulfan and cytarabine versus standard BuCy2 for patients with acute myeloid leukemia: a prospective, randomized phase II study","volume":"54","author":"Zhang","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.07.023_bib42","article-title":"Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtha.2024.07.023_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30322","article-title":"Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders","volume":"70","author":"Fraser","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jtha.2024.07.023_bib44","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15068","article-title":"Foxp3(+) regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis","volume":"8","author":"Pierini","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtha.2024.07.023_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtha.2024.07.023_bib46","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2024.07.023_bib47","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hum.2023.056","article-title":"Immune responses to muscle-directed adeno-associated viral gene transfer in clinical studies","volume":"34","author":"Kumar","year":"2023","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.jtha.2024.07.023_bib48","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1182\/blood.V68.3.762.762","article-title":"Expression of antigens of the platelet glycoprotein IIb\/IIIa complex on human hematopoietic stem cells","volume":"68","author":"Fraser","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.023_bib49","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood.V93.9.2898.409k17_2898_2906","article-title":"Glycoprotein IIb-IIIa is expressed on avian multilineage hematopoietic progenitor cells","volume":"93","author":"Ody","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.023_bib50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/blood-2008-12-193888","article-title":"Surface antigen phenotypes of hematopoietic stem cells from embryos and murine embryonic stem cells","volume":"114","author":"McKinney-Freeman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.023_bib51","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.07.023_bib52","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtha.2024.07.023_bib53","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41409-022-01705-7","article-title":"A\u00a0randomized phase III study of pretransplant conditioning for AML\/MDS with fludarabine and once daily IV busulfan\u00a0+\/- clofarabine in allogeneic stem cell transplantation","volume":"57","author":"Andersson","year":"2022","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T20:57:16Z","timestamp":1762030636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1538783624004434"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.023","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}